What the September draft proposed
NICE’s updated draft proposed Endotest, a saliva-based microRNA test, for use during a four-year evidence-generation period. The proposal was for specified circumstances alongside standard assessment, rather than as a replacement for clinical judgement.
The draft concluded that EndoSure, DotEndo and Endomkit needed more research. A further committee meeting was scheduled for 18 November 2026. Check the linked NICE development page for decisions made after this article’s update date.
What the study showed
A 2025 multicentre validation study reported encouraging diagnostic accuracy in 971 participants with symptoms suggestive of endometriosis. Most participants already had a high likelihood of the condition. The study was funded by the test’s developer.
Results from that population do not automatically show how the test performs in every primary-care patient with pelvic pain. The RCOG highlights the need for independent validation across more varied populations and everyday clinical pathways.
What this could mean for you
A diagnostic test is useful when its result helps make a better decision. Ask:
- Would it change the next step in my assessment?
- How would a negative result be interpreted?
- Would I still need imaging or specialist referral?
- Is this routine care, a research study or a privately purchased test?
Ask your clinical team which investigations are appropriate and available in your circumstances.
Information sources
- NICE: September 2026 draft update
- NICE: diagnostic technologies development page
- RCOG: clinical statement, July 2026 (PDF)
- Original study: saliva microRNA validation, 2025
General information to support your consultation. Individual assessment is needed to decide on treatment.